CD19 and acute lymphoblastic leukemia: Taken together, these findings document the ability of sub-cytotoxic RT doses to upregulate DR and CD19 on the surface of ALL cells, in vitro and in vivo, de facto increasing their susceptibility to CART19 cell-mediated killing.